Comparison of Two Artificial Liver Support Treatments for Acute-on-Chronic Liver Failure
NCT07931742, Not yet recruiting, The Second Affiliated Hospital of Chongqing Medical University
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Comparison of Two Artificial Liver Support Treatments for Acute-on-Chronic Liver Failure | ClinicalTrials.gov |
| NCT number | NCT07931742 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 400 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The Second Affiliated Hospital of Chongqing Medical University | ClinicalTrials.gov |
| Conditions | Acute-on-Chronic Liver Failure (ACLF) | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | 90-Day Transplant-Free Survival | From enrollment through Day 90 | The percentage of participants who are alive and have not undergone liver transplantation at Day 90 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first. | ClinicalTrials.gov |
| Secondary | 28-Day Transplant-Free Survival | From enrollment through Day 28 | The percentage of participants who are alive and have not undergone liver transplantation at Day 28 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first. | ClinicalTrials.gov |
| Secondary | Occurrence of Liver Transplantation | From enrollment through Day 90 | The percentage of participants who undergo liver transplantation during follow-up. The date of transplantation is recorded. | ClinicalTrials.gov |
| Secondary | Change in Hepatic Encephalopathy Grade | Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment | Change in West Haven hepatic encephalopathy grade from baseline at each follow-up assessment, categorized as improvement, no change, or worsening. | ClinicalTrials.gov |
| Secondary | Reversal of Hepatorenal Syndrome | Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment | Percentage of participants with hepatorenal syndrome at baseline who meet the prespecified criteria for reversal at each follow-up assessment. Hepatorenal syndrome is diagnosed according to the International Club of Ascites criteria specified in the study protocol. | ClinicalTrials.gov |
| Secondary | Correction of Hyponatremia | Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment | Percentage of participants with hyponatremia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum sodium measurements. | ClinicalTrials.gov |
| Secondary | Correction of Hyperkalemia | Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment | Percentage of participants with hyperkalemia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum potassium measurements. | ClinicalTrials.gov |
| Secondary | Change From Baseline in SOFA Score | Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment | Change in the Sequential Organ Failure Assessment (SOFA) score from baseline at each follow-up assessment. The total score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction. | ClinicalTrials.gov |
| Secondary | Relative Change in Total Bilirubin From Baseline During Serial Treatment and Follow-up | Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment | elative change in total bilirubin from baseline at each subsequent treatment-related and follow-up assessment, using the prespecified calculation method. Treatment-related measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session. Both increases and decreases are recorded. | ClinicalTrials.gov |
| Secondary | Change in Blood Ammonia From Baseline | Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment | Change in blood ammonia concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. | ClinicalTrials.gov |
| Secondary | Change in Serum Creatinine From Baseline | Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment | Change in serum creatinine concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. | ClinicalTrials.gov |
| Secondary | Change in INR From Baseline | Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment | Change in the international normalized ratio (INR) from baseline at each postbaseline assessment. Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)